Perfusion of cat paws with compound 48/80 released two slow reacting substances (SRSs) which were isolated and characterized as 5-hydroxy-S-cysteinylglycyl-7,9,-11,14-icosatetraenoic acid (SRS I) and -hydroxy-6S-cysteinyl-7,9,11,14-icosatetraenoic acid (SRS II) on the basis of chemical degradations, amino acid analyses, spectroscopic and enzymic experiments, and comparison with synthetic samples. The smooth muscle-contractile activities of synthetic 5-hydroxy-6 y-glutamylcysteinylglycyl-7,9,11,14-icosatetraenoic acid, synthetic5-hydroxy--S-cysteinyl-7,9,11,14-icosatetraenoic acid, and SRS II were not inactivated by arylsulfatase. On the other hand, the spasmogenic activities produced by synthetic 5-hydroxy-6S-cysteinylglycyl-7,9,11,14-icosatetraenoic acid and SRS I were destroyed at the same rate by the arylsulfatase. This mode of inactivation was attributed to an aminopeptidase activity in the arylsulfatase preparation because 5-ydroxyl-6-Scysteinyl-7,9,11,14-icosatetraenoic acid was isolated and identified as the reaction end product. Because the properties of SRS from cat paws closely resemble those of SRS generated by immunological stimulation of human tissues (SRS-A) and because all known SRS-A are inactivated by arylsulfatases, we contend that 5-hydroxy-6S-cysteinylglycyl-7,9,11,14-icosatetraenoic acid (SRS I) corresponds to SRS-A.
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In 1938, Feldberg and Kellaway (1) first described a substance that caused the guinea pig ileum to contract more slowly and with more sustained action than did histamine; they named the compound "slow reacting substance (SRS)." Two years later, Kellaway and Trethewie (2) reported that slow reacting substance of anaphylaxis (SRS-A) was released from sensitized tissue by a specific antigen. Subsequently, it was shown (3) that SRS-A was one of several pharmacologic mediators that may be important in human asthma. SRS has since been found to be released from many types of tissues and cell suspensions including guinea pig, rabbit, monkey, bovine, and human lungs (4) (5) (6) , cat paws (7, 8) , isolated rat mast cells (9) , human leukocytes (10) and nasal polyps (11) , human and rat leukemic basophils (12, 13) , and rat peritoneal fluid (14, 15) .
Here we present our studies on the purification and identification of two SRSs from cat paws after perfusion with Compound 48/80 (16) and biochemical evidence supporting the contention that SRS I corresponds to SRS-A. (,uC18 ) preparative column (0.94 X 50 cm) of Partisil-10 M9 ODS (Whatman) was used for SRS purification. The radial compression separation system consisted of a Waters radial compression module (RCM-100) with a radial-Pak C18 cartridge (0.8 X 10 cm).
MATERIALS AND METHODS

Materials
SRS Assay. SRS bioactivity was assayed on guinea pig ileum segments by a modification of the procedure reported by Chakravarty (17) . Histamine was assayed in the presence of atropine (1 MM) and SRS was assayed in the presence of atropine (1 ,uM) and mepyramine (1 ,M) . One unit of SRS was defined as that amount of SRS which caused a contraction with a peak height equal to that induced by 5 ng of histamine base. After the log-dose-response curve for histamine was determined, a similar curve of an in-house standard of SRS was determined and from this the other SRS samples were quantitated. Only aqueous samples were bioassayed. Samples that had been evaporated to dryness were redissolved in 0.1% NH40H because water did not completely dissolve the sample. Large quantities (0.5 ml) of NH40H at this concentration had no effect on the ileum response. Samples of SRS were assayed in the presence of 20-40 nM FPL 55712, a reversible SRS inhibitor (18) .
Cat Paw Perfusion. Cat paws were perfused by a modification of the procedure reported by Hogberg et al. (19) . Cats (1.5-5 kg) of either sex were anesthetized with sodium pentobarbital (50 mg/kg; intraperitoneally) and subsequently killed with an intravenous injection of 1 ml of saturated KCl. Immediately after the death of the animal, the main artery of each paw was cannulated with polyethylene tubing (0.6 mm inside diameter). The paws were cut off above the ankle joint and hung from a hook in a water-jacketed jar which was maintained at 25°C by a water circulating pump. The paws were perfused with a 154 mM NaCl/0.9 mM CaCl2/2.7 mM KCl containing 10% (vol/vol) S6rensen phosphate buffer (Na2HPO4 + KH2PO4, 67 mM) at pH 7.0. This buffered salt solution was maintained at 25°C and was simultaneously perfused through the set of four paws from each cat with a four-channel peristaltic pump. After the paws were perfused for 45 min to remove most of the blood, 50 Mg of the releasing factor (Compound 48/80) was administered and the perfusion was conAbbreviations: SRS, slow-reacting substance; SRS-A, SRS of anaphylaxis; HPLC, high-pressure liquid chromatography; 5-HPETE, 5-hydroperoxy-6-trans-8,11,14-cis-icosatetraenoic acid; SRS-Cys, 5-hydroxy-6-S-cysteinyl-7,9,11,14-icosatetraenoic acid; SRS-Cys-Gly, 5-hydroxy-6-S-cysteinylglycyl-7,9,11,14-icosatetraenoic acid; leukotriene A, 5-trans-5,6-oxido-7,9,11,14-icosatetraenoic acid; SRS-GSH, 5 -hydroxy-6-'-glutamylcysteinylglycyl-7,9,11,14-icosatetraenoic acid. * To whom reprint requests should be addressed.
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tinued for an additional 180 min. During this period, the effluents were collected by gravity drainage into flasks-cooled to 40C.
Purification. The ice-cold perfusate (4-4.5 liters) from two cats was passed over an XAD-7 column (2.2 X 17 cm). After the column was washed with 100 ml of distilled water followed by 20 The reactions of leukotriene A methyl ester with glutathione, cysteinylglycine, and cysteine were carried out by the method described by Corey et al. (21) . The desired SRSs were purified by HPLC on a Radial Pak C18 cartridge (0.8 X 10 cm) in a Radial compression separation system (RCM-100). SRS-GSH was eluted at 13 min (flow rate, 2 ml/min) with a mobile phase of MeOH/H20, 55:45 (vol/vol), containing 0.05% acetic acid buffered to pH 5.4 (NH40H). SRS-Cys-Gly and SRS-Cys had retention times of 7.5 and 11 min, respectively, with MeOH/ H20, 7:3, containing 0.05% acetic acid buffered to pH 5.4 (NH40H) (flow rate, 2.5 ml/min).
RESULTS
Using a purification procedure consisting of XAD-7 column chromatography, ethyl acetate extraction, and reverse-phase HPLC (preparative MC18), we have purified two SRSs from cat paw perfusates with an overall recovery of 20% ( Table 1 ). The elution profiles of SRS I and SRS II from the reverse-phase HPLC column are shown in Fig. 1 . SRS I was eluted after 13 min and had a specific activity of 4400 units/nmol (based on e 40,000 at 280 nm). SRS II was eluted from the column at 15.4 mm and had a specific activity of 65 units/nmol. SRS I and SRS II had identical UV absorption spectra with absorption maxima at 280 nm and shoulders at 270 and 292 nm (Fig. 2) . Exposure of either SRS I or SRS II to soybean lipoxygenase resulted in a rapid loss of bioactivity accompaiiied by a shift of uv absorption maximum from 280 to 308 nm (Fig. 3) . Amino acid analyses after acid hydrolysis of SRS I gave cysteine and glycine in a ratio of 0.5:1; SRS II afforded cysteine 3 . Dose-response curves for SRS I, SRS II, synthetic SRS-GSH, SRS-Cys-Gly, and SRS-Cys, and histamine on isolated guinea pig ileum. The amount of SRS was calculated from the absorbance at 280 rim, assuming e = 40,000. elimination product, 5-oxo-icosa-6-trans-8,11,14-cis-tetraenoic acid methyl ester. SN2 displacement of the epoxide in leukotriene A by the respective nucleophiles (21) (cysteine, cysteinylglycine, and glutathione) gave the corresponding adducts as pairs of diastereomers which were not separable by HPLC under various conditions.
All three synthetic products (two diastereomers) (SRS-CysGiy, SRS-Cys, and SRS-GSH) had UV absorption maxima at 280 nm with characteristic shoulders at 270 and 292 nm. The rate of inactivation and the associated spectral change observed upon treatment with soybean lipoxygenase and the retention times on HPLC [preparative jaC18, MeOH/H20, 1:1 (vol/vol); and Radial-Pak C18, MeOH/H20, 7:3 buffered at pH 5.4] of synthetic SRS-Cys-Gly and SRS-Cys were indistinguishable from the corresponding properties of SRS I and SRS II, respectively. Also, the slopes of the log-dose-contractile response curves (Fig. 3) of synthetic SRS-cys and SRS-Cys-Gly coincided with those of SRS II and SRS I, respectively. In addition, the patterns of reversal of the contractile activity by FPL 55712 for SRS II and SRS I were found to be indistinguishable from those of corresponding synthetic derivatives. On the other hand, synthetic SRS-GSH had a specific activity of 650 units/nmol but its pattern of contractile response was only partially reversed by FPL 55712; it was only slowly attacked by soybean lipoxygenase.
The spasmogenic activities of synthetic SRS-Cys-Gly and SRS I were inactivated at approximately the same rate by a limpet arylsulfatase preparation whereas the bioactivities of synthetic SRS-GSH, synthetic SRS-Cys, and SRS II were not diminished (Fig. 4) . The small loss of bioactivity by SRS II is due to the contamination of a trace quantity of SRS I in the SRS II sample. When synthetic-SRS-Cys-Gly was incubated with arylsulfatase for 30 min, a less-polar product was formed (Fig. 5) agreement with the supposition that SRS I and SRS II contain 5-hydroxy-7,9,11,14-icbsatetraenoic acid as the fatty acid portion of the molecule but differ in the thioether substituent at C-6. Anmino acid and NH2-terminal sequence analyses revealed that the anoint acid portion of the molecule in SRS I is cysteinylglycine and in SRS II is cysteine. Although the mechanism for the generation of cysteine after strong acid hydrolysis is not understood, it was apparent that the thioether linkages in these molecules were cleaved because synthetic SRS-GSH likewise afforded cysteine upon acidic hydrolysis (Table 2) . These results strongly suggest that the structure of SRS I is 5-hydroxy-6-S-cysteinylglycyl-7,9,11,14-icosatetraenoic acid and that of SRS II is 5-hydroxy-6-S-cysteinyl-7,9,11,14-icosatetraenoic acid.
The presence of a sulfate group in SRS-A had been repeatedly proposed on the basis of arylsulfitase inactivation experiments (25, 26) . Because SRS I also is readily inactivated by arylsulfatase (Fig. 4) and there existed the possibility that some labile group in SRS I and SRS II was lost dining chemical degradative studies, we decided to verify their identities by chemical synthesis.
The transformation of (+)-5-HPETE methyl ester into leukotriene A methyl ester requires the selective abstraction of a C-10 proton and activation of the hydroperoxyl group at C-5.
After many unsuccessful attempts, it was found that reaction of (+)-5-HPETE methyl ester with methanesulfonyl chloride and a hindered base such as methylcyclohexylamine (to minimize 1,2-elimination) at lbw temperatures afforded, in 15% yield, the desired leukotriene A methyl ester whose spectral properties were in good agreement with those derived from independent chemical syntheses (27, 28) . Introduction of the thio subsfituents was effected by reaction of leukotriene A with the respective nucleophiles. Although we have been unable to separate the two diastereomners of the synthetic derivatives, it is noteworthy that the properties of the diastereomeric mixtures of synthetic SRS-Cys and SRS-Cys-Gly agreed well with the corresponding properties of SRS II and SRS I, lending further support to our structural assignment.
The inactivation of SRS-A by arylsulfatase had been a longstanding enigma. The availability of synthetic substances of known chemical identities allowed us to define this mode of inactivation. Although the bioactivities of synthetic SRS-GSH, SRS-Cys, and SRS II were not inactivated by the Limpet arylsulfatase preparation, the contractile activities of synthetic SRS-Cys-Gly and SRS I were destroyed at approximately the same rate by the arylsulfatase. Because SRS-Cys was identified as the reaction product after exposure of SRS-Cys-Gly to arylsulfatase, one can now conclude that this inactivation was the result of the cleavage of the cysteinyl-glycine peptide bond and not the result of the hydrolysis of a sulfate ester. At the present time, it is not known whether arylsulfatase per se possesses both esteratic and peptidatic activities similar to chymotrypsin. Highly purified arylsulfatase (29) was reported to inactivate SRS-A, and very low concentrations of SRS-A served as a competitive inhibitor during the hydrolyses of arylsulfate esters catalyzed by arylsuifatase. Alternatively, it is also possible that aryfsulfatase preparations are contaminated with an aminopeptidase responsible for the cleavage of S-Cys-Gly derivatives, similar to those found in the kidney (g9). It is noteworthy that y-glutamyl transpeptidase and leukotrienes were also reported to be present in kidney tissues (30, 31) .
During the preparation of this manuscript, two groups reported the isolation of 5-hydroxy-6-S-cysteinylglycyl-7,9,11,14-icosatetraenoic acid from rat basophil leukemic (RBL-1) cells (32, 33 the structure of an SRS from murine mastocytoma cells to be 5-hydroxy-6-S-cysteinyl-7,9,11,14-icosatetraenoic acid and termed it "leukotriene C," this structural assignment was later revised and 5-hydroxy-6-'y-glutamylcysteinylglycyl-7,9,11,14-icosatetraenoic acid was named "leukotriene C' (22) .
Because SRS from cat paws closely resembles SRS formed by immunological stimulation of human tissues (13) and because all known SRS-A have been reported to be inactivated by arylsulfatases (25, 26, 29, 35) , we contend that 5-hydroxy-6-Scysteinylglycyl-7,9,11,14-icosatetraenoic acid (SRS I) corresponds to SRS-A.
One may envisage that SRS I (SRS-A) could arise via an enzyme-catalyzed SN2 attack of cysteinylglycine on the epoxide in leukotriene A, or it could be derived from the precursor, leukotriene C, by the action of y-glutamyl transpeptidase (3) . In turn, leukotriene C could originate from leukotriene A via the action of glutathione transferase (36) . The cleavage of the cysteinylglycine peptide bond converts the highly bioactive SRS I (SRS-A) into a much less bioactive SRS II (Fig. 6 ). This inactivation mechanism may play an important role in the regulation of the effective levels of SRS-A within the tissues.
